Becor Communications Inc. Announces a Name Change to Enhance Biotech, Inc., and Stock Trading Symbol Change.

Business Editors

ENCINO, Calif.--(BUSINESS WIRE)--April 2, 2003

Becor Communications Inc. (OTCBB:BCOI) today announced it has changed its name to Enhance Biotech, Inc. As a result, effective Tuesday April 2, 2003, the Company's shares will be traded on the over-the-counter Bulletin Board system under the symbol EBOI.

As previously announced, the Company has signed a definitive agreement to acquire 100% of all the outstanding shares of Enhance Lifesciences Inc., a privately held Delaware company. It is anticipated that the transaction will close by April 15th 2003.

Enhance Lifesciences, Inc. is an emerging biopharmaceutical company that is focused on the acquisition, development and commercialization of "Lifestyle Drugs" in the main therapeutic lifestyle disorder categories. The Company currently has six products in development targeted against Sexual Dysfunction, IVF, Depression, Anti-Cellulite, Anti-Aging and arthritis. These six initial categories have a combined projected marketplace value of in excess of $29 billion by 2007 according to a recent report on the sector. Over the past ten years the pharmaceutical industry has spent over $20 billion in R&D on lifestyle drugs.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Enhance Lifesciences' compounds under development in particular; the potential failure of Enhance Lifesciences' compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhance Lifesciences' compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhance Lifesciences' business, structure or projections; the development of competing products; uncertainties related to Enhance Lifesciences' dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under the Company's prior name Becor Communications, Inc. The Company and Enhance Lifesciences disclaim any obligation to update these forward-looking statements.